Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Bullboard Posts
Post by Chetwyndblueon Oct 28, 2010 12:16pm
408 Views
Post# 17624523

NioGold's $20 million JV with Aurizon is a game ch

NioGold's $20 million JV with Aurizon is a game ch

October 28, 2010
NioGold’s $20 Million Joint Venture with Aurizon is a Game Changer

Primary Value Drivers:

  • 50,000 meter drill program now underway on NioGold’s 100% owned Marban project by Aurizon Mines, who is earning a 50% interest in exchange for a CA$20 million investment in drilling plus a cash payment for ½ the gold resources estimated at CA$20+ million ;
  • Advanced exploration targets on past producing projects in historically prolific Malartic-Val d'Or Mining Camps;
  • Quebec is the world’s number 1 mining jurisdiction as rated by the Fraser Institute of Canada;
  • Fully funded CA$20 million deposit delineation and exploration campaign without share dilution;
  • Partnership with Aurizon will fast-track identification of additional resources and potentially reserves for a future mine.
  • Aggressive exploration of remaining 90% of property package and continuing land acquisition provide significant upside potential through new discovery.

Please find below a link to the full research report on NioGold by the Midas Letter

https://www.midasletter.com/subscribers/MidasLetter_Premium_NOX_101026.pdf


Bullboard Posts